Ophthalmic Business News

As we are in early 2023, we plan to use this column to provide a high-level update on new developments in tax and asset protection planning, and hope these updates prompt some physicians to look into these areas early in the year.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news stories, live from Hawaiian Eye.

The FDA cleared an investigational new drug application from HuidaGene Therapeutics for a clinical trial of HG004 for the treatment of RPE65 mutation-associated inherited retinal dystrophies, according to a press release.

Dagny Zhu, MD, Cathleen M. McCabe, MD, and Laura M. Periman, MD, talk with Cynthia A. Matossian, MD, FACS, about the multitude of career pathways in ophthalmology and balancing career with family.

Ocuphire Pharma reported oral APX3330 for the treatment of diabetic retinopathy failed to meet the primary endpoint in the phase 2 ZETA-1 trial but achieved key secondary measures.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Gavin Herbert, Tom Burns, Andy Corley and Tom Mitro to discuss their days at Allergan and what they have learned from their experiences.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Richard L. Lindstrom, MD, previews the advantages of a new topical anesthetic.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Shawn O’Neil of ViaLase discusses positive 24-month safety and efficacy data for the company’s noninvasive OCT-driven femtosecond laser for glaucoma treatment.

KOLOA, Hawaii — Bausch + Lomb has announced that an affiliate of the company has acquired AcuFocus.

KOLOA, Hawaii — Reinventing oneself is possible at all stages in life, according to a speaker here.